Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
---|---|---|---|---|---|
IDEAYA BIOSCIENCES | 12 | 3 | -4,31 % | ||
BIONTECH | 11 | 13 | -6,46 % | ||
SUMMIT THERAPEUTICS | 7 | 12 | -18,75 % | ||
RAPPORT THERAPEUTICS | 7 | - | +131,54 % | ||
ALKERMES | 5 | 8 | +3,12 % | ||
HARROW | 5 | 4 | +9,09 % | ||
REGENERON PHARMACEUTICALS | 4 | 22 | -3,11 % | ||
CG ONCOLOGY | 4 | - | +2,16 % | ||
ALNYLAM PHARMACEUTICALS | 3 | 9 | +0,54 % | ||
EVOLUS | 3 | 3 | -2,29 % |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16:42 | PTC Therapeutics stock remains BofA top pick for 2025 on Sephience potential | 3 | Investing.com | ||
16:42 | Ascendis Pharma stock remains BofA top pick for 2025 on Yorvipath launch | 4 | Investing.com | ||
16:42 | BofA Securities reiterates Buy rating on Merus stock, citing strong outlook | 3 | Investing.com | ||
16:42 | BofA Securities reaffirms Buy rating on argenx stock with $887 target | 3 | Investing.com | ||
16:34 | UroGen Pharma: Krebsmedikament Zosduri zielt auf 5-Milliarden-Dollar-Markt | 1 | Investing.com Deutsch | ||
16:34 | Mirum Pharmaceuticals auf Morgan Stanley Konferenz: Strategische Einblicke und erhöhte Umsatzprognose | 2 | Investing.com Deutsch | ||
16:26 | Moderna-Aktie leicht im Minus (20,4636 €) | 216 | ARIVA.de | Im Minus liegt gegenwärtig das Wertpapier von Moderna . Die Aktie kostete zuletzt 24,04 US-Dollar. Ein Minus in Höhe von 1,09 US-Dollar müssen derzeit die Aktionäre von Moderna hinnehmen. Das Papier... ► Artikel lesen | |
16:22 | TD Cowen bestätigt Kaufempfehlung für Rapport Therapeutics nach starken Studiendaten | 1 | Investing.com Deutsch | ||
16:18 | $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today | 2 | Benzinga.com | ||
16:18 | Rapport Therapeutics stock rating reiterated as Buy by TD Cowen | 2 | Investing.com | ||
15:45 | Summit Therapeutics Crashes After Failing To Deliver Another Merck-Walloping Punch | 16 | Investor's Business Daily | ||
15:42 | BMO Capital raises Alnylam Pharmaceuticals stock price target on Zilebesiran potential | 1 | Investing.com | ||
15:42 | Tevogen announces $9-11 billion valuation for COVID-19 T cell therapy | 1 | Investing.com | ||
15:39 | Opendoor, Almonty Industries, BioNTech - Great opportunities outside the tech bubble | 108 | The Market Herald Canada | ||
15:34 | Zilebesiran-Potenzial: BMO Capital erhöht Kursziel für Alnylam | 3 | Investing.com Deutsch | ||
15:34 | Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth? | 2 | Zacks | ||
15:31 | Biontech: Aktie schießt nach oben - Insider sprechen vom "Gamechanger"!!! | Hebelschein-Spekulant | |||
15:30 | Tevogen Bio Inc: Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell Platform | 2 | GlobeNewswire (USA) | ||
15:29 | Evolus Names Tatjana Mitchell As CFO | 1 | RTTNews | ||
15:22 | Regeneron auf Morgan-Stanley-Konferenz: Strategisches Potenzial der Produktpipeline | 10 | Investing.com Deutsch |